Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

dbSNP Short Genetic Variations

Welcome to the Reference SNP (rs) Report

All alleles are reported in the Forward orientation. Click on the Variant Details tab for details on Genomic Placement, Gene, and Amino Acid changes. HGVS names are in the HGVS tab.

Reference SNP (rs) Report

This page reports data for a single dbSNP Reference SNP variation (RefSNP or rs) from the new redesigned dbSNP build.
Top of the page reports a concise summary for the rs, with more specific details included in the corresponding tabs below.
All alleles are reported in the Forward orientation. Use the Genomic View to inspect the nucleotides flanking the variant, and its neighbors.
For more information see Help documentation.

rs121913237

Current Build 156

Released September 21, 2022

Organism
Homo sapiens
Position
chr1:114716126 (GRCh38.p14) Help

The anchor position for this RefSNP. Includes all nucleotides potentially affected by this change, thus it can differ from HGVS, which is right-shifted. See here for details.

Alleles
C>A / C>G / C>T
Variation Type
SNV Single Nucleotide Variation
Frequency
T=0.000008 (2/251484, GnomAD_exome)
T=0.000014 (2/140208, GnomAD)
T=0.000008 (1/121410, ExAC) (+ 2 more)
T=0.00008 (3/35432, ALFA)
T=0.00008 (1/13006, GO-ESP)
Clinical Significance
Reported in ClinVar
Gene : Consequence
NRAS : Missense Variant
Publications
35 citations
Genomic View
See rs on genome

ALFA Allele Frequency
The ALFA project provide aggregate allele frequency from dbGaP. More information is available on the project page including descriptions, data access, and terms of use.

Release Version: 20230706150541
Population Group Sample Size Ref Allele Alt Allele
Total Global 35432 C=0.99992 T=0.00008
European Sub 26588 C=0.99989 T=0.00011
African Sub 2918 C=1.0000 T=0.0000
African Others Sub 114 C=1.000 T=0.000
African American Sub 2804 C=1.0000 T=0.0000
Asian Sub 112 C=1.000 T=0.000
East Asian Sub 86 C=1.00 T=0.00
Other Asian Sub 26 C=1.00 T=0.00
Latin American 1 Sub 500 C=1.000 T=0.000
Latin American 2 Sub 628 C=1.000 T=0.000
South Asian Sub 98 C=1.00 T=0.00
Other Sub 4588 C=1.0000 T=0.0000


Help

Frequency tab displays a table of the reference and alternate allele frequencies reported by various studies and populations. Table lines, where Population="Global" refer to the entire study population, whereas lines, where Group="Sub", refer to a study-specific population subgroupings (i.e. AFR, CAU, etc.), if available. Frequency for the alternate allele (Alt Allele) is a ratio of samples observed-to-total, where the numerator (observed samples) is the number of chromosomes in the study with the minor allele present (found in "Sample size", where Group="Sub"), and the denominator (total samples) is the total number of all chromosomes in the study for the variant (found in "Sample size", where Group="Study-wide" and Population="Global").

Download
Study Population Group Sample Size Ref Allele Alt Allele
gnomAD - Exomes Global Study-wide 251484 C=0.999992 T=0.000008
gnomAD - Exomes European Sub 135410 C=0.999985 T=0.000015
gnomAD - Exomes Asian Sub 49008 C=1.00000 T=0.00000
gnomAD - Exomes American Sub 34592 C=1.00000 T=0.00000
gnomAD - Exomes African Sub 16256 C=1.00000 T=0.00000
gnomAD - Exomes Ashkenazi Jewish Sub 10078 C=1.00000 T=0.00000
gnomAD - Exomes Other Sub 6140 C=1.0000 T=0.0000
gnomAD - Genomes Global Study-wide 140208 C=0.999986 T=0.000014
gnomAD - Genomes European Sub 75936 C=0.99997 T=0.00003
gnomAD - Genomes African Sub 42008 C=1.00000 T=0.00000
gnomAD - Genomes American Sub 13658 C=1.00000 T=0.00000
gnomAD - Genomes Ashkenazi Jewish Sub 3320 C=1.0000 T=0.0000
gnomAD - Genomes East Asian Sub 3132 C=1.0000 T=0.0000
gnomAD - Genomes Other Sub 2154 C=1.0000 T=0.0000
ExAC Global Study-wide 121410 C=0.999992 T=0.000008
ExAC Europe Sub 73352 C=0.99999 T=0.00001
ExAC Asian Sub 25166 C=1.00000 T=0.00000
ExAC American Sub 11578 C=1.00000 T=0.00000
ExAC African Sub 10406 C=1.00000 T=0.00000
ExAC Other Sub 908 C=1.000 T=0.000
Allele Frequency Aggregator Total Global 35432 C=0.99992 T=0.00008
Allele Frequency Aggregator European Sub 26588 C=0.99989 T=0.00011
Allele Frequency Aggregator Other Sub 4588 C=1.0000 T=0.0000
Allele Frequency Aggregator African Sub 2918 C=1.0000 T=0.0000
Allele Frequency Aggregator Latin American 2 Sub 628 C=1.000 T=0.000
Allele Frequency Aggregator Latin American 1 Sub 500 C=1.000 T=0.000
Allele Frequency Aggregator Asian Sub 112 C=1.000 T=0.000
Allele Frequency Aggregator South Asian Sub 98 C=1.00 T=0.00
GO Exome Sequencing Project Global Study-wide 13006 C=0.99992 T=0.00008
GO Exome Sequencing Project European American Sub 8600 C=0.9999 T=0.0001
GO Exome Sequencing Project African American Sub 4406 C=1.0000 T=0.0000
Help

Variant Details tab shows known variant placements on genomic sequences: chromosomes (NC_), RefSeqGene, pseudogenes or genomic regions (NG_), and in a separate table: on transcripts (NM_) and protein sequences (NP_). The corresponding transcript and protein locations are listed in adjacent lines, along with molecular consequences from Sequence Ontology. When no protein placement is available, only the transcript is listed. Column "Codon[Amino acid]" shows the actual base change in the format of "Reference > Alternate" allele, including the nucleotide codon change in transcripts, and the amino acid change in proteins, respectively, allowing for known ribosomal slippage sites. To view nucleotides adjacent to the variant use the Genomic View at the bottom of the page - zoom into the sequence until the nucleotides around the variant become visible.

Genomic Placements
Sequence name Change
GRCh38.p14 chr 1 NC_000001.11:g.114716126C>A
GRCh38.p14 chr 1 NC_000001.11:g.114716126C>G
GRCh38.p14 chr 1 NC_000001.11:g.114716126C>T
GRCh37.p13 chr 1 NC_000001.10:g.115258747C>A
GRCh37.p13 chr 1 NC_000001.10:g.115258747C>G
GRCh37.p13 chr 1 NC_000001.10:g.115258747C>T
NRAS RefSeqGene (LRG_92) NG_007572.1:g.5769G>T
NRAS RefSeqGene (LRG_92) NG_007572.1:g.5769G>C
NRAS RefSeqGene (LRG_92) NG_007572.1:g.5769G>A
Gene: NRAS, NRAS proto-oncogene, GTPase (minus strand)
Molecule type Change Amino acid[Codon] SO Term
NRAS transcript NM_002524.5:c.35G>T G [GGT] > V [GTT] Coding Sequence Variant
GTPase NRas NP_002515.1:p.Gly12Val G (Gly) > V (Val) Missense Variant
NRAS transcript NM_002524.5:c.35G>C G [GGT] > A [GCT] Coding Sequence Variant
GTPase NRas NP_002515.1:p.Gly12Ala G (Gly) > A (Ala) Missense Variant
NRAS transcript NM_002524.5:c.35G>A G [GGT] > D [GAT] Coding Sequence Variant
GTPase NRas NP_002515.1:p.Gly12Asp G (Gly) > D (Asp) Missense Variant
Help

Clinical Significance tab shows a list of clinical significance entries from ClinVar associated with the variation, per allele. Click on the RCV accession (i.e. RCV000001615.2) or Allele ID (i.e. 12274) to access full ClinVar report.

Allele: A (allele ID: 48940 )
ClinVar Accession Disease Names Clinical Significance
RCV000037576.4 Noonan syndrome Pathogenic
RCV000158986.5 not provided Pathogenic
RCV000419124.1 Melanoma Pathogenic
RCV000421072.1 Multiple myeloma Likely-Pathogenic
RCV000423890.1 Gastric adenocarcinoma Likely-Pathogenic
RCV000429393.1 Acute myeloid leukemia Likely-Pathogenic
RCV000432178.1 Myelodysplastic syndrome Likely-Pathogenic
RCV000438750.1 Malignant melanoma of skin Likely-Pathogenic
RCV000438967.1 Malignant neoplasm of body of uterus Likely-Pathogenic
RCV000439421.1 Neoplasm of the large intestine Pathogenic
RCV001377735.4 RASopathy Likely-Pathogenic
RCV001781336.1 Noonan syndrome 6 Pathogenic
Allele: G (allele ID: 216786 )
ClinVar Accession Disease Names Clinical Significance
RCV000203450.2 Myelodysplastic syndrome progressed to acute myeloid leukemia Pathogenic
RCV000380895.2 not provided Pathogenic
RCV000418647.1 Multiple myeloma Likely-Pathogenic
RCV000425963.1 Myelodysplastic syndrome Likely-Pathogenic
RCV000426950.1 Acute myeloid leukemia Likely-Pathogenic
RCV000427550.1 Non-small cell lung carcinoma Pathogenic
RCV000433455.1 Gastric adenocarcinoma Likely-Pathogenic
RCV000434113.1 Melanoma Pathogenic
RCV000437165.1 Malignant neoplasm of body of uterus Likely-Pathogenic
RCV000444591.1 Malignant melanoma of skin Likely-Pathogenic
RCV000444670.1 Neoplasm of the large intestine Pathogenic
RCV001324275.4 RASopathy Uncertain-Significance
RCV001813426.1 Noonan syndrome and Noonan-related syndrome Pathogenic
Allele: T (allele ID: 48247 )
ClinVar Accession Disease Names Clinical Significance
RCV000032849.7 Epidermal nevus Pathogenic
RCV000144963.3 Juvenile myelomonocytic leukemia Pathogenic
RCV000158980.4 not provided Pathogenic-Likely-Pathogenic
RCV000417702.1 Multiple myeloma Likely-Pathogenic
RCV000417869.1 Melanoma Pathogenic
RCV000424239.1 Myelodysplastic syndrome Likely-Pathogenic
RCV000427949.1 Neoplasm of the large intestine Pathogenic
RCV000430706.1 Malignant neoplasm of body of uterus Likely-Pathogenic
RCV000434517.1 Gastric adenocarcinoma Likely-Pathogenic
RCV000436228.1 Acute myeloid leukemia Likely-Pathogenic
RCV000439064.1 Non-small cell lung carcinoma Pathogenic
RCV000440963.1 Malignant melanoma of skin Likely-Pathogenic
RCV001781333.2 Noonan syndrome 6 Pathogenic
RCV001813214.1 Noonan syndrome and Noonan-related syndrome Likely-Pathogenic
RCV001852659.3 RASopathy Pathogenic
Help

Aliases tab displays HGVS names representing the variant placements and allele changes on genomic, transcript and protein sequences, per allele. HGVS name is an expression for reporting sequence accession and version, sequence type, position, and allele change. The column "Note" can have two values: "diff" means that there is a difference between the reference allele (variation interval) at the placement reported in HGVS name and the reference alleles reported in other HGVS names, and "rev" means that the sequence of this variation interval at the placement reported in HGVS name is in reverse orientation to the sequence(s) of this variation in other HGVS names not labeled as "rev".

Placement C= A G T
GRCh38.p14 chr 1 NC_000001.11:g.114716126= NC_000001.11:g.114716126C>A NC_000001.11:g.114716126C>G NC_000001.11:g.114716126C>T
GRCh37.p13 chr 1 NC_000001.10:g.115258747= NC_000001.10:g.115258747C>A NC_000001.10:g.115258747C>G NC_000001.10:g.115258747C>T
NRAS RefSeqGene (LRG_92) NG_007572.1:g.5769= NG_007572.1:g.5769G>T NG_007572.1:g.5769G>C NG_007572.1:g.5769G>A
NRAS transcript NM_002524.5:c.35= NM_002524.5:c.35G>T NM_002524.5:c.35G>C NM_002524.5:c.35G>A
NRAS transcript NM_002524.4:c.35= NM_002524.4:c.35G>T NM_002524.4:c.35G>C NM_002524.4:c.35G>A
GTPase NRas NP_002515.1:p.Gly12= NP_002515.1:p.Gly12Val NP_002515.1:p.Gly12Ala NP_002515.1:p.Gly12Asp
Help

Submissions tab displays variations originally submitted to dbSNP, now supporting this RefSNP cluster (rs). We display Submitter handle, Submission identifier, Date and Build number, when the submission appeared for the first time. Direct submissions to dbSNP have Submission ID in the form of an ss-prefixed number (ss#). Other supporting variations are listed in the table without ss#.

17 SubSNP, 5 Frequency, 40 ClinVar submissions
No Submitter Submission ID Date (Build)
1 DF-BWCC ss275515057 Nov 22, 2010 (133)
2 DF-BWCC ss275515072 Nov 22, 2010 (133)
3 DF-BWCC ss275515076 Nov 22, 2010 (133)
4 NHLBI-ESP ss712334771 Apr 25, 2013 (138)
5 EVA_EXAC ss1685703232 Apr 01, 2015 (144)
6 HUMAN_LONGEVITY ss2165908682 Dec 20, 2016 (150)
7 GNOMAD ss2731737989 Nov 08, 2017 (151)
8 EVA_DECODE ss3687577231 Jul 12, 2019 (153)
9 EVA ss3823644661 Apr 25, 2020 (154)
10 GNOMAD ss4000854876 Apr 25, 2021 (155)
11 CSS-BFX ss5442107659 Oct 12, 2022 (156)
12 CSS-BFX ss5442107660 Oct 12, 2022 (156)
13 CSS-BFX ss5442107661 Oct 12, 2022 (156)
14 EVA ss5847552186 Oct 12, 2022 (156)
15 EVA ss5935520791 Oct 12, 2022 (156)
16 EVA ss5935520792 Oct 12, 2022 (156)
17 EVA ss5979286867 Oct 12, 2022 (156)
18 ExAC NC_000001.10 - 115258747 Oct 11, 2018 (152)
19 gnomAD - Genomes NC_000001.11 - 114716126 Apr 25, 2021 (155)
20 gnomAD - Exomes NC_000001.10 - 115258747 Jul 12, 2019 (153)
21 GO Exome Sequencing Project NC_000001.10 - 115258747 Oct 11, 2018 (152)
22 ALFA NC_000001.11 - 114716126 Apr 25, 2021 (155)
23 ClinVar RCV000032849.7 Oct 11, 2018 (152)
24 ClinVar RCV000037576.4 Oct 12, 2022 (156)
25 ClinVar RCV000144963.3 Oct 11, 2018 (152)
26 ClinVar RCV000158980.4 Oct 12, 2022 (156)
27 ClinVar RCV000158986.5 Oct 12, 2022 (156)
28 ClinVar RCV000203450.2 Oct 12, 2022 (156)
29 ClinVar RCV000380895.2 Oct 11, 2018 (152)
30 ClinVar RCV000417702.1 Oct 11, 2018 (152)
31 ClinVar RCV000417869.1 Oct 11, 2018 (152)
32 ClinVar RCV000418647.1 Oct 11, 2018 (152)
33 ClinVar RCV000419124.1 Oct 11, 2018 (152)
34 ClinVar RCV000421072.1 Oct 11, 2018 (152)
35 ClinVar RCV000423890.1 Oct 11, 2018 (152)
36 ClinVar RCV000424239.1 Oct 11, 2018 (152)
37 ClinVar RCV000425963.1 Oct 11, 2018 (152)
38 ClinVar RCV000426950.1 Oct 11, 2018 (152)
39 ClinVar RCV000427550.1 Oct 11, 2018 (152)
40 ClinVar RCV000427949.1 Oct 11, 2018 (152)
41 ClinVar RCV000429393.1 Oct 11, 2018 (152)
42 ClinVar RCV000430706.1 Oct 11, 2018 (152)
43 ClinVar RCV000432178.1 Oct 11, 2018 (152)
44 ClinVar RCV000433455.1 Oct 11, 2018 (152)
45 ClinVar RCV000434113.1 Oct 11, 2018 (152)
46 ClinVar RCV000434517.1 Oct 11, 2018 (152)
47 ClinVar RCV000436228.1 Oct 11, 2018 (152)
48 ClinVar RCV000437165.1 Oct 11, 2018 (152)
49 ClinVar RCV000438750.1 Oct 11, 2018 (152)
50 ClinVar RCV000438967.1 Oct 11, 2018 (152)
51 ClinVar RCV000439064.1 Oct 11, 2018 (152)
52 ClinVar RCV000439421.1 Oct 11, 2018 (152)
53 ClinVar RCV000440963.1 Oct 11, 2018 (152)
54 ClinVar RCV000444591.1 Oct 11, 2018 (152)
55 ClinVar RCV000444670.1 Oct 11, 2018 (152)
56 ClinVar RCV001324275.4 Oct 12, 2022 (156)
57 ClinVar RCV001377735.4 Oct 12, 2022 (156)
58 ClinVar RCV001781333.2 Oct 12, 2022 (156)
59 ClinVar RCV001781336.1 Oct 12, 2022 (156)
60 ClinVar RCV001813214.1 Oct 12, 2022 (156)
61 ClinVar RCV001813426.1 Oct 12, 2022 (156)
62 ClinVar RCV001852659.3 Oct 12, 2022 (156)
Help

History tab displays RefSNPs (Associated ID) from previous builds (Build) that now support the current RefSNP, and the dates, when the history was updated for each Associated ID (History Updated).

Associated ID History Updated (Build)
rs121913249 May 05, 2011 (133)
rs121913253 May 05, 2011 (133)
Added to this RefSNP Cluster:
Submission IDs Observation SPDI Canonical SPDI Source RSIDs
ss2731737989, ss5442107659, ss5847552186, ss5935520791 NC_000001.10:115258746:C:A NC_000001.11:114716125:C:A (self)
RCV000037576.4, RCV000158986.5, RCV000419124.1, RCV000421072.1, RCV000423890.1, RCV000429393.1, RCV000432178.1, RCV000438750.1, RCV000438967.1, RCV000439421.1, RCV001377735.4, RCV001781336.1, ss275515076 NC_000001.11:114716125:C:A NC_000001.11:114716125:C:A (self)
ss5442107660, ss5935520791 NC_000001.10:115258746:C:G NC_000001.11:114716125:C:G
RCV000203450.2, RCV000380895.2, RCV000418647.1, RCV000425963.1, RCV000426950.1, RCV000427550.1, RCV000433455.1, RCV000434113.1, RCV000437165.1, RCV000444591.1, RCV000444670.1, RCV001324275.4, RCV001813426.1, ss275515072 NC_000001.11:114716125:C:G NC_000001.11:114716125:C:G (self)
4913593, 762403, 103289, ss712334771, ss1685703232, ss2731737989, ss3823644661, ss5442107661, ss5847552186, ss5935520791, ss5935520792, ss5979286867 NC_000001.10:115258746:C:T NC_000001.11:114716125:C:T (self)
RCV000032849.7, RCV000144963.3, RCV000158980.4, RCV000417702.1, RCV000417869.1, RCV000424239.1, RCV000427949.1, RCV000430706.1, RCV000434517.1, RCV000436228.1, RCV000439064.1, RCV000440963.1, RCV001781333.2, RCV001813214.1, RCV001852659.3, 23382970, 3162538035, ss275515057, ss2165908682, ss3687577231, ss4000854876 NC_000001.11:114716125:C:T NC_000001.11:114716125:C:T (self)
Help

Publications tab displays PubMed articles citing the variation as a listing of PMID, Title, Author, Year, Journal, ordered by Year, descending.

35 citations for rs121913237
PMID Title Author Year Journal
2278970 RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study. Vogelstein B et al. 1990 Genes, chromosomes & cancer
2674680 N-ras mutations in human cutaneous melanoma from sun-exposed body sites. van 't Veer LJ et al. 1989 Molecular and cellular biology
3122217 RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. Janssen JW et al. 1987 Proceedings of the National Academy of Sciences of the United States of America
8120410 Ras mutations in human melanoma: a marker of malignant progression. Ball NJ et al. 1994 The Journal of investigative dermatology
12460918 BRAF and RAS mutations in human lung cancer and melanoma. Brose MS et al. 2002 Cancer research
14982869 Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Tartaglia M et al. 2004 Blood
15046639 Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. Houben R et al. 2004 Journal of carcinogenesis
15831708 Repressible transgenic model of NRAS oncogene-driven mast cell disease in the mouse. Wiesner SM et al. 2005 Blood
15951308 RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Bowen DT et al. 2005 Blood
16273091 BRAF mutation predicts sensitivity to MEK inhibition. Solit DB et al. 2006 Nature
16291983 Distinct sets of genetic alterations in melanoma. Curtin JA et al. 2005 The New England journal of medicine
16434492 Implications of NRAS mutations in AML: a study of 2502 patients. Bacher U et al. 2006 Blood
17332249 Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Matsuda K et al. 2007 Blood
17699718 AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Davies BR et al. 2007 Molecular cancer therapeutics
18390968 Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. Adjei AA et al. 2008 Journal of clinical oncology
18948947 Somatic mutations affect key pathways in lung adenocarcinoma. Ding L et al. 2008 Nature
18952898 RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia. Kim WI et al. 2009 Blood
19075190 High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Tyner JW et al. 2009 Blood
19657110 Recurring mutations found by sequencing an acute myeloid leukemia genome. Mardis ER et al. 2009 The New England journal of medicine
20130576 RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Hatzivassiliou G et al. 2010 Nature
20179705 RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Poulikakos PI et al. 2010 Nature
20619739 Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. De Roock W et al. 2010 The Lancet. Oncology
20736745 NRAS mutations are rare in colorectal cancer. Irahara N et al. 2010 Diagnostic molecular pathology
21305640 Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Vaughn CP et al. 2011 Genes, chromosomes & cancer
21729679 Development of molecular biomarkers in individualized treatment of colorectal cancer. De Mattos-Arruda L et al. 2011 Clinical colorectal cancer
21829508 PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. Janku F et al. 2011 PloS one
22144181 Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. Xu J et al. 2012 Blood
22407852 RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group. Sano H et al. 2012 International journal of hematology
22499344 Keratinocytic epidermal nevi are associated with mosaic RAS mutations. Hafner C et al. 2012 Journal of medical genetics
23414587 MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Ascierto PA et al. 2013 The Lancet. Oncology
23515407 Characteristics of lung cancers harboring NRAS mutations. Ohashi K et al. 2013 Clinical cancer research
24033266 A systematic approach to assessing the clinical significance of genetic variants. Duzkale H et al. 2013 Clinical genetics
24284627 Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness. Li Q et al. 2013 Nature
25157968 Prospective enterprise-level molecular genotyping of a cohort of cancer patients. MacConaill LE et al. 2014 The Journal of molecular diagnostics
26619011 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Chang MT et al. 2016 Nature biotechnology
Help

The Flanks tab provides retrieving flanking sequences of a SNP on all molecules that have placements.

Genome context:
Select flank length:

Genomic regions, transcripts, and products
Top Help

NCBI Graphical Sequence Viewer display of the genomic region, transcripts and protein products for the reported RefSNP (rs).
Use the zoom option to view the nucleotides around the RefSNP and find other neighboring RefSNPs.
Visit Sequence Viewer for help with navigating inside the display and modifying the selection of displayed data tracks.

Software version is: 2.0.1.post761+d5e8e07